Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Once Daily PMR vs Twice Daily Cilostazol IR in Healthy Volunteers
NCT05466734Phase 1Completed
- Sponsor
- Genovate Biotechnology
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cilostazol in intermittent claudication (IC) (2 arms), sponsored by Genovate Biotechnology. Primary endpoints: Area under the curve, from time zero to last measureable time point and Area under the curve from time zero to infinity. Started Jul 2022; status: completed.
02
Drugs
cilostazol
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT05466734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466734.